| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Tsugiyasu Kanda | |
| Daisuke Usuda | |||
| P2860 | cites work | PPAR delta: a dagger in the heart of the metabolic syndrome | Q24541527 |
| Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis | Q24541529 | ||
| PPARs and the cardiovascular system | Q24642728 | ||
| Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat | Q24799696 | ||
| Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy | Q27666968 | ||
| Mode of peroxisome proliferator-activated receptor γ activation by luteolin | Q27677850 | ||
| Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network | Q28259101 | ||
| Peroxisome proliferator-activated receptor gamma in diabetes and metabolism | Q28263756 | ||
| International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors | Q28276138 | ||
| Effects of mitogen-activated protein kinase pathway and co-activator CREP-binding protein on peroxisome proliferator-activated receptor-gamma-mediated transcription suppression of angiotensin II type 1 receptor gene | Q28567283 | ||
| Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade | Q28575720 | ||
| Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats | Q28577083 | ||
| Fat and beyond: the diverse biology of PPARgamma | Q29615416 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Peroxisome proliferator-activated receptor γ in diabetes and metabolism | Q30040168 | ||
| PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism | Q33283063 | ||
| PPARalpha: energy combustion, hypolipidemia, inflammation and cancer | Q33805104 | ||
| Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
| Thiazolidinediones | Q34346862 | ||
| Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly | Q34386587 | ||
| PPAR gamma and human metabolic disease | Q34416432 | ||
| From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions | Q34494167 | ||
| Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother | Q34518606 | ||
| A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma | Q34527082 | ||
| Transcription coactivators for peroxisome proliferator-activated receptors | Q34575776 | ||
| Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. | Q34582444 | ||
| Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension | Q35608633 | ||
| Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease | Q35636191 | ||
| Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity | Q35714622 | ||
| PPARs and LXRs: atherosclerosis goes nuclear | Q35756515 | ||
| Adiponectin and cardiovascular health: an update | Q35859734 | ||
| Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ | Q35969865 | ||
| Peroxisome Proliferator Activated Receptor-α Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice | Q36119361 | ||
| Corepressors of agonist-bound nuclear receptors | Q36288161 | ||
| Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance | Q36321335 | ||
| The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects | Q36445381 | ||
| PPAR Action in Human Placental Development and Pregnancy and Its Complications | Q36446678 | ||
| Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect | Q36491985 | ||
| Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. | Q36497543 | ||
| Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors | Q36733873 | ||
| Peroxisome proliferator-activated receptor-gamma in vascular biology | Q36855383 | ||
| Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders | Q36907353 | ||
| PPAR activation: a new target for the treatment of hypertension | Q36912093 | ||
| Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha | Q36949274 | ||
| Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension | Q36982658 | ||
| PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators | Q37002053 | ||
| Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. | Q37098752 | ||
| PPARbeta/delta ligands as modulators of the inflammatory response | Q37157763 | ||
| Redefining the role of thiazolidinediones in the management of type 2 diabetes | Q37167551 | ||
| Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention | Q37193503 | ||
| Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? | Q37201071 | ||
| Integration of metabolism and inflammation by lipid-activated nuclear receptors | Q37225357 | ||
| Direct antiatherosclerotic effects of PPAR agonists | Q37365530 | ||
| Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages | Q37395127 | ||
| Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages | Q37417623 | ||
| Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease | Q37422668 | ||
| PPARs: the vasculature, inflammation and hypertension | Q37478019 | ||
| Next generation multifunctional angiotensin receptor blockers | Q37588484 | ||
| PPARs and adipocyte function. | Q37601619 | ||
| Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. | Q37659128 | ||
| Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? | Q37686890 | ||
| Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease | Q37796517 | ||
| PPARγ agonist beyond glucose lowering effect. | Q37857704 | ||
| PPARs and their effects on the cardiovascular system | Q37896654 | ||
| Effects of PPARγ agonists against vascular and renal dysfunction | Q37961918 | ||
| PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders | Q37961926 | ||
| The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases | Q37989830 | ||
| The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology | Q38125773 | ||
| Peroxisome proliferator-activated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-beta | Q40170432 | ||
| Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α. | Q42197114 | ||
| The effects of a PPARalpha agonist on myocardial damage in obese diabetic mice with heart failure | Q43013934 | ||
| TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. | Q43090071 | ||
| Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma | Q43993728 | ||
| Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension | Q44275921 | ||
| Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study | Q44804350 | ||
| Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats | Q45056023 | ||
| Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice | Q45256389 | ||
| PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. | Q46006542 | ||
| Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial | Q46060880 | ||
| Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats | Q46843920 | ||
| Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo | Q46847915 | ||
| Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. | Q50988205 | ||
| Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. | Q51773528 | ||
| Role of PPAR in cardiovascular diseases | Q80551181 | ||
| Pleiotropic effects of ARB in metabolic syndrome | Q82810616 | ||
| P433 | issue | 8 | |
| P921 | main subject | hypertension | Q95566669 |
| P304 | page(s) | 744-754 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | World journal of cardiology | Q27723312 |
| P1476 | title | Peroxisome proliferator-activated receptors for hypertension | |
| P478 | volume | 6 |
| Q35841988 | Activation of central PPAR-γ attenuates angiotensin II-induced hypertension. |
| Q39018398 | Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation. |
| Q38911344 | Association of peroxisome proliferator-activated receptor delta and additional gene-smoking interaction on cardiovascular disease |
| Q38369606 | Associations between PPARG polymorphisms and the risk of essential hypertension |
| Q55312903 | Associations between hypertension and the peroxisome proliferator-activated receptor-δ (PPARD) gene rs7770619 C>T polymorphism in a Korean population. |
| Q53653452 | Case-control study on association of peroxisome proliferator-activated receptor-δ and SNP-SNP interactions with essential hypertension in Chinese Han population. |
| Q26741144 | Cigarette smoking impairs nitric oxide-mediated cerebral blood flow increase: Implications for Alzheimer's disease |
| Q55004979 | Early Postweaning Treatment with Dimethyl Fumarate Prevents Prenatal Dexamethasone- and Postnatal High-Fat Diet-Induced Programmed Hypertension in Male Rat Offspring. |
| Q41189367 | Effect of keishibukuryogan on genetic and dietary obesity models. |
| Q37397863 | Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway |
| Q36870154 | Hypolipidemic effects of chitosan and its derivatives in hyperlipidemic rats induced by a high-fat diet |
| Q89047768 | Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension |
| Q47190496 | Maternal High Fructose Intake Increases the Vulnerability to Post-Weaning High-Fat Diet-Induced Programmed Hypertension in Male Offspring |
| Q57049117 | Maternal Melatonin Therapy Attenuates Methyl-Donor Diet-Induced Programmed Hypertension in Male Adult Rat Offspring |
| Q38919677 | PPAR-α Activation Mediates Innate Host Defense through Induction of TFEB and Lipid Catabolism |
| Q26771825 | PPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic Syndrome |
| Q38674739 | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. |
| Q26746998 | Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis |
| Q36261125 | Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions |
| Q47775156 | Prediction and Subtyping of Hypertension from Pan-Tissue Transcriptomic and Genetic Analyses |
| Q39148023 | Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease |
| Q41975402 | Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport |
| Q46204521 | The endocannabinoid system in cardiovascular function: novel insights and clinical implications |
Search more.